FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588917083> ?p ?o ?g. }

• W2588917083 endingPage "vi238" @default.
• W2588917083 startingPage "vi238" @default.
• W2588917083 abstract "MTBs are routinely used and a requirement for comprehensive cancer centers. However, the impact of MTB is not well characterized. We studied the recommendations of MTBs on the clinical outcomes of all HCC patients presented at our liver MTB, in comparison to the 2005 practice guidelines of the American Association for the Study of Liver Disease (AASLD). Data were retrospectively collected for all patients with newly diagnosed HCC and presented to our liver MTB. Patients were followed up until the time of death, there last known follow-up or time of transplantation. Patients were staged at baseline using the Barcelona Clinic Liver Cancer (BCLC) staging classification. Median overall survival (OS) rates were calculated using a standard Kaplan-Meier and Cox regression model with SPSS software (v. 23). A 312 patients out of 380 were enrolled. The average age was 62.8 years with 77.9% males. Hepatitis C was the most common etiology of HCC (57.7%). In our cohort 51% of the MTB recommendations were adherent to the guidelines. The first line treatment suggested by the MTB and its adherence with AASLD guidelines by stage are shown in Table 1. Our data shows that adherence to AASLD guidelines was associated with significantly longer OS in BCLC A by 21 months (HR 1.59; 95% CI 1.26-2.02). On the other hand, the OS was significantly longer in BCLC D that was not treated according to the AASLD guidelines by 7 months (HR 0.413; 95% CI 0.25-0.69). Many patients in BCLC B/C did not receive AASLD recommended treatment, and their OS were not any different.Tabled 1First line treatment and Adherence to AASLD GuidelinesTreatmentBCLC A n = 139BCLC B n = 56BCLC C n = 83BCLC D n = 34Surgical resection327142Transplant referral24306RFA28300Cyberknife7351Y901111101TACE2815121Sorafenib35213Clinical trial0100Supportive care682120Adherence to AASLD guidelines (%)73.3%26.8%25.3%58.8% Open table in a new tab In clinical practice, the adherence to published guidelines is limited and subject to the heterogeneity of the patients and their comorbidities. MTB had a positive impact on BCLC D OS. The findings in our study suggest the need to refine the current staging and guidelines for HCC, especially for BCLC B, C, and D. MTBs need to have a bigger role in facilitating clinical trial participation." @default.
• W2588917083 created "2017-02-24" @default.
• W2588917083 creator A5020594501 @default.
• W2588917083 creator A5048007683 @default.
• W2588917083 creator A5060270349 @default.
• W2588917083 creator A5081330024 @default.
• W2588917083 date "2016-10-01" @default.
• W2588917083 modified "2023-10-09" @default.
• W2588917083 title "Utility of multidisciplinary tumor board (MTB) in the management of hepatocellular cancer (HCC)" @default.
• W2588917083 doi "https://doi.org/10.1093/annonc/mdw371.97" @default.
• W2588917083 hasPublicationYear "2016" @default.
• W2588917083 type Work @default.
• W2588917083 sameAs 2588917083 @default.
• W2588917083 citedByCount "2" @default.
• W2588917083 countsByYear W25889170832020 @default.
• W2588917083 countsByYear W25889170832022 @default.
• W2588917083 crossrefType "journal-article" @default.
• W2588917083 hasAuthorship W2588917083A5020594501 @default.
• W2588917083 hasAuthorship W2588917083A5048007683 @default.
• W2588917083 hasAuthorship W2588917083A5060270349 @default.
• W2588917083 hasAuthorship W2588917083A5081330024 @default.
• W2588917083 hasBestOaLocation W25889170831 @default.
• W2588917083 hasConcept C121608353 @default.
• W2588917083 hasConcept C126322002 @default.
• W2588917083 hasConcept C143998085 @default.
• W2588917083 hasConcept C2776231280 @default.
• W2588917083 hasConcept C2776455275 @default.
• W2588917083 hasConcept C2777075537 @default.
• W2588917083 hasConcept C2778019345 @default.
• W2588917083 hasConcept C2779609443 @default.
• W2588917083 hasConcept C2911091166 @default.
• W2588917083 hasConcept C2993652001 @default.
• W2588917083 hasConcept C50382708 @default.
• W2588917083 hasConcept C71924100 @default.
• W2588917083 hasConcept C72563966 @default.
• W2588917083 hasConcept C90924648 @default.
• W2588917083 hasConceptScore W2588917083C121608353 @default.
• W2588917083 hasConceptScore W2588917083C126322002 @default.
• W2588917083 hasConceptScore W2588917083C143998085 @default.
• W2588917083 hasConceptScore W2588917083C2776231280 @default.
• W2588917083 hasConceptScore W2588917083C2776455275 @default.
• W2588917083 hasConceptScore W2588917083C2777075537 @default.
• W2588917083 hasConceptScore W2588917083C2778019345 @default.
• W2588917083 hasConceptScore W2588917083C2779609443 @default.
• W2588917083 hasConceptScore W2588917083C2911091166 @default.
• W2588917083 hasConceptScore W2588917083C2993652001 @default.
• W2588917083 hasConceptScore W2588917083C50382708 @default.
• W2588917083 hasConceptScore W2588917083C71924100 @default.
• W2588917083 hasConceptScore W2588917083C72563966 @default.
• W2588917083 hasConceptScore W2588917083C90924648 @default.
• W2588917083 hasLocation W25889170831 @default.
• W2588917083 hasOpenAccess W2588917083 @default.
• W2588917083 hasPrimaryLocation W25889170831 @default.
• W2588917083 hasRelatedWork W1900878195 @default.
• W2588917083 hasRelatedWork W1987726814 @default.
• W2588917083 hasRelatedWork W2051266851 @default.
• W2588917083 hasRelatedWork W2056262915 @default.
• W2588917083 hasRelatedWork W2103967320 @default.
• W2588917083 hasRelatedWork W2290980437 @default.
• W2588917083 hasRelatedWork W2885353048 @default.
• W2588917083 hasRelatedWork W3015716288 @default.
• W2588917083 hasRelatedWork W3032796845 @default.
• W2588917083 hasRelatedWork W3113289614 @default.
• W2588917083 hasVolume "27" @default.
• W2588917083 isParatext "false" @default.
• W2588917083 isRetracted "false" @default.
• W2588917083 magId "2588917083" @default.
• W2588917083 workType "article" @default.